AlphaFold and the Future of Precision Drugs
For decades, biology has faced a fundamental challenge: understanding how the information encoded in our genes translates into the physical machinery of life….
-
-
Is Pharmacogenomics Paired with AI the Antidote to the Global Cardiovascular Crisis?
Cardiovascular disease remains the world’s leading cause of death, claiming close to 20 million lives each year, with cases continuing to rise across…
-
New UK Guideline: Clopidogrel Now Requires Genetic Testing
The UK has taken a major step forward in precision prescribing with the publication of its first national pharmacogenomic guideline, focused on the…
-
The Three Key Factors Driving the Rise of Preemptive Pharmacogenomics
For years, pharmacogenomics (PGx) was seen as a future promise, a fascinating science that could someday make drug therapy safer and more effective….
-
FDA’s Final Rule on Laboratory-Developed Tests: Implications for Pharmacogenomics
In May 2024, the U.S. Food and Drug Administration (FDA) published a final rule that would bring laboratory-developed tests (LDTs) explicitly under the…
-
APGxA Interview Series: Dr. Gualberto Ruaño, M.D., Ph.D. — Physician Scientist, Innovator, and Entrepreneur
When you talk to Dr. Gualberto Ruaño, you don’t just hear about science — you hear about purpose. A physician, geneticist, and entrepreneur,…
-
The Pharmacogenomics Technology Market: Trends, Insights, and Opportunities
Grand View Research has just released its latest report on the pharmacogenomics technology market, offering fresh insights into one of the fastest-growing areas…
-
How to Navigate FDA Warnings About Unapproved Pharmacogenomic Claims
Pharmacogenetic testing has emerged as one of the most exciting frontiers in personalized medicine. By analyzing a patient’s genetic makeup, these tests promise…
-
What You Should Know About Pharmacogenomic Variant Annotation
The promise of precision medicine lies in its ability to tailor treatments to the genetic makeup of each patient. Pharmacogenomics is central to…
-
Pharmacogenomic Data Submission: Guidelines for Clinicians and Industry Professionals
This blog provides a comprehensive overview of the FDA’s current and draft guidance on pharmacogenomic data submission, highlighting key regulatory requirements, submission algorithms, voluntary submissions, and practical considerations for clinicians and industry professionals.
End of content
End of content